<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02867267</url>
  </required_header>
  <id_info>
    <org_study_id>ZDX-2015-11</org_study_id>
    <nct_id>NCT02867267</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Ta1 for Sepsis</brief_title>
  <acronym>TESTS</acronym>
  <official_title>The Efficacy and Safety of Thymosin Alpha 1 for Sepsis: a Multicenter , Double-Blinded, Randomized and Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether thymalfasin is safe and effective in
      patients who have sepsis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our previous study reported that the 7-day treatment of Ta 1 demonstrated positive active
      effect as to the 28-day all-cause mortality and the augmentation of mHLA-DR (monocyte Human
      Leukocyte Antigen DR) at the secondary endpoint. Therefore, we intend to verify this finding
      through a randomized, double-blind and placebo-controlled clinical trial and the trail will
      include subjects with impaired immunologic functions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28-day all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary infection (recurrence, double infection and new infection) from Day 0 to 28</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day clearance rate of pathogenic microorganism</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stays</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stays</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day re-hospitalization rate</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score (at days -1, 7, 14 and 28)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day ventilator-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day ICU-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day CRRT-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-day Vasoactive agents-free days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variance of the count of monocyte human lymphocyte antigens (mHLA) -DR at days 7, 14 and 28 compared with the baseline (day -1)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The count of Treg cells at days -1 and 7</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1106</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>thymosin alpha 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1ml subcutaneous injection with 1.6 mg thymalfasin for 7 days, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1ml subcutaneous injection with 1.6 mg placebo for 7 days , BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymosin alpha 1</intervention_name>
    <description>Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.</description>
    <arm_group_label>thymosin alpha 1</arm_group_label>
    <other_name>thymalfasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injections of 1.6 mg twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤85

          2. Signed informed consent signed

          3. Presence of at least one acute and severe organ failure related to sepsis and at least
             one SOFA&gt;1

          4. Infected focus are confirmed or suspected and satisfy at least one of the followings:

               1. pathogenic microbes grow in blood and at aseptic locations

               2. presence of abscess or partially-infected tissues

               3. suspected infection identified by at least one of the following evidences:

                    -  leukocytes at normal aseptic locations

                    -  organic perforation (confirmed by imaging evidence, examination result or
                       intestinal content leak during drainage)

                    -  Imaging evidence of pneumonia accompanied by purulent secretion

                    -  Related syndromes with high infection risk (cholangitis for example)

        Exclusion Criteria:

          1. History of organ or bone marrow transplantation

          2. Systemic autoimmune disease

          3. Under pregnancy or in suckling period

          4. Presence of hematologic malignancies

          5. The patient is inclined to stop or cancel the artificial intervention for sustaining
             life, in other words, has abandoned treatment

          6. The patient could die of an underlying disease within 28 days or is in end-stage

          7. The patient could die within 24 hours

          8. The patient has undergone CPR in the past 72 hours and the neuromechanism has not
             fully recovered

          9. The patient has in the past 30 days undergone certain clinical drug or instrument
             trials which could affect immunity (such as Xuebijing, ulinastatin and CRRT)

         10. The patient has a medical history of allergy or intolerance to thymalfasin

         11. The source of infection cannot be contained, for example: infections that cannot be
             hanlded during surgical operations and drainage

         12. The patient does not timely perform relevant test items in 24 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guan Xiangdong, M. D</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wu Jianfeng, M. D</last_name>
    <phone>020-87755766</phone>
    <phone_ext>8454</phone_ext>
    <email>wujianfeng9571@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pei Fei, M. M</last_name>
    <email>peif26@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou Feihu, M. D</last_name>
      <email>zhoufh301@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Long Yun, M. D</last_name>
      <phone>010-69152303</phone>
      <email>Ly_icu@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 309th Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ma Penglin, M. D</last_name>
      <phone>010-66775014</phone>
      <email>Mapenglin1@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhou Lixin, M. D</last_name>
      <phone>0757-83162516</phone>
      <email>Drzhoulixin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang Shouhong, M.D</last_name>
      <phone>020-83827812</phone>
      <email>wshdoctor@139.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Medical Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Zhijie, M. D</last_name>
      <phone>020-81332339</phone>
      <email>Hezhijie2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yimin, M. D</last_name>
      <phone>020-83062905</phone>
      <email>dryiminli@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kou Qiuye, M. D</last_name>
      <phone>020-38254043</phone>
      <email>kouqiuye@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wu Jianfeng, M.D</last_name>
      <phone>020-87755766</phone>
      <phone_ext>8454</phone_ext>
      <email>wujiafeng9571@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Guan Xiangdong, M.D</last_name>
      <phone>020-87755766</phone>
      <phone_ext>8456</phone_ext>
      <email>carlg@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Guan Xiangdong, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wu Jianfeng, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Commend</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Weiqin, M. D</last_name>
      <phone>025-80861658</phone>
      <email>liweiqindr@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Erzhen, M. D</last_name>
      <phone>021-4370045</phone>
      <phone_ext>665896</phone_ext>
      <email>chenerzhen@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhu Duming, M. D</last_name>
      <phone>021-64041990</phone>
      <phone_ext>2724</phone_ext>
      <email>duming_zhu@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kang Yan, M. D</last_name>
      <phone>028-85422508</phone>
      <email>Kangyan_hx@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cui Wei, M. D</last_name>
      <phone>0571-87783632</phone>
      <email>iamcuiwei@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Jing, M. D</last_name>
      <phone>0571-87987373</phone>
      <email>zjicu@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sun Renhuang, M. D</last_name>
      <phone>0571-85893283</phone>
      <email>Jqin168@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wu J, Zhou L, Liu J, Ma G, Kou Q, He Z, Chen J, Ou-Yang B, Chen M, Li Y, Wu X, Gu B, Chen L, Zou Z, Qiang X, Chen Y, Lin A, Zhang G, Guan X. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care. 2013 Jan 17;17(1):R8. doi: 10.1186/cc11932.</citation>
    <PMID>23327199</PMID>
  </results_reference>
  <results_reference>
    <citation>Romani L, Bistoni F, Montagnoli C, Gaziano R, Bozza S, Bonifazi P, Zelante T, Moretti S, Rasi G, Garaci E, Puccetti P. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007 Sep;1112:326-38. Epub 2007 May 10. Review.</citation>
    <PMID>17495242</PMID>
  </results_reference>
  <results_reference>
    <citation>Romani L, Moretti S, Fallarino F, Bozza S, Ruggeri L, Casagrande A, Aversa F, Bistoni F, Velardi A, Garaci E. Jack of all trades: thymosin α1 and its pleiotropy. Ann N Y Acad Sci. 2012 Oct;1269:1-6. doi: 10.1111/j.1749-6632.2012.06716.x. Review.</citation>
    <PMID>23045964</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Li W, Niu C, Pan L, Li N, Li J. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011 Jun;34(3):198-202. doi: 10.1007/s10753-010-9224-1. Erratum in: Inflammation. 2011 Jun;34(3):222-3.</citation>
    <PMID>20549321</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wu Jianfeng</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>thymosin alpha 1; thymalfasin; sepsis; immunodepression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

